- Home
- NBIX vs BEN Comparison
NBIX vs BEN Comparison
Compare NBIX & BEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- BEN
- Stock Information
- Founded
- NBIX 1992
- BEN 1947
- Country
- NBIX United States
- BEN United States
- Employees
- NBIX N/A
- BEN N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- BEN Investment Managers
- Sector
- NBIX Health Care
- BEN Finance
- Exchange
- NBIX Nasdaq
- BEN Nasdaq
- Market Cap
- NBIX 13.2B
- BEN 13.1B
- IPO Year
- NBIX 1996
- BEN N/A
- Fundamental
- Price
- NBIX $128.91
- BEN $23.92
- Analyst Decision
- NBIX Strong Buy
- BEN Hold
- Analyst Count
- NBIX 22
- BEN 12
- Target Price
- NBIX $165.59
- BEN $21.13
- AVG Volume (30 Days)
- NBIX 935.9K
- BEN 4.2M
- Earning Date
- NBIX 07-30-2025
- BEN 08-01-2025
- Dividend Yield
- NBIX N/A
- BEN 5.34%
- EPS Growth
- NBIX 2.97
- BEN N/A
- EPS
- NBIX 3.39
- BEN 0.53
- Revenue
- NBIX $2,509,900,000.00
- BEN $8,638,200,000.00
- Revenue This Year
- NBIX $16.12
- BEN N/A
- Revenue Next Year
- NBIX $15.06
- BEN $3.92
- P/E Ratio
- NBIX $38.04
- BEN $45.40
- Revenue Growth
- NBIX 18.42
- BEN 7.38
- 52 Week Low
- NBIX $84.23
- BEN $16.25
- 52 Week High
- NBIX $157.98
- BEN $25.36
- Technical
- Relative Strength Index (RSI)
- NBIX 46.34
- BEN 46.51
- Support Level
- NBIX $130.75
- BEN $24.48
- Resistance Level
- NBIX $137.44
- BEN $24.84
- Average True Range (ATR)
- NBIX 3.60
- BEN 0.52
- MACD
- NBIX -0.71
- BEN -0.18
- Stochastic Oscillator
- NBIX 33.88
- BEN 51.19
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About BEN Franklin Resources Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of June 2025, Franklin had $1.606 trillion in managed assets, composed primarily of equity (41%), fixed-income (28%), multi-asset/balanced (11%) funds, alternatives (16%) and money market funds (4%). Distribution tends to be weighted between retail investors (55% of AUM) and institutional accounts (42%), with high-net-worth clients accounting for the remainder. Franklin is one of the more global of the US-based asset managers we cover, with 30% of its assets under management invested in global/international strategies and just as much sourced from clients domiciled outside the United States.